Mostrar el registro sencillo del ítem
dc.contributor.author
Sanchez Sanchez, Maria Victoria
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Ebensen, Thomas
dc.contributor.author
Schulze, Kai
dc.contributor.author
Cargnelutti, Diego Esteban
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Scodeller, Eduardo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Guzmán, Carlos A.
dc.date.available
2024-03-13T15:47:53Z
dc.date.issued
2023-03
dc.identifier.citation
Sanchez Sanchez, Maria Victoria; Ebensen, Thomas; Schulze, Kai; Cargnelutti, Diego Esteban; Scodeller, Eduardo; et al.; Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG; MDPI; Pharmaceutics; 15; 3; 3-2023; 1-22
dc.identifier.issn
1999-4923
dc.identifier.uri
http://hdl.handle.net/11336/230425
dc.description.abstract
Current influenza vaccines target highly variable surface glycoproteins; thus, mismatchesbetween vaccine strains and circulating strains often diminish vaccine protection. For this reason,there is still a critical need to develop effective influenza vaccines able to protect also against thedrift and shift of different variants of influenza viruses. It has been demonstrated that influenzanucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providingcross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine usingthe recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinylamido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared withthat observed following parenteral vaccination of mice with the same formulation. Mice vaccinatedwith 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showedenhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immuneresponses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specificIgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvantedformulation as compared with those of the non-adjuvanted vaccination group. The addition ofBPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized byrobust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable thatthe immune responses elicited by the novel formulation administered by the i.n. route were able toconfer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
MDPI
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
BPPcysMPEG
dc.subject
MALP-2
dc.subject
INFLUENZA
dc.subject
MUCOSA
dc.subject
ADJUVANT
dc.subject
VACCINE
dc.subject
NUCLEOPROTEIN
dc.subject
TLR2/6 AGONIST
dc.subject.classification
Enfermedades Infecciosas
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-03-13T15:22:32Z
dc.journal.volume
15
dc.journal.number
3
dc.journal.pagination
1-22
dc.journal.pais
Suiza
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Basel
dc.description.fil
Fil: Sanchez Sanchez, Maria Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
dc.description.fil
Fil: Ebensen, Thomas. Helmholtz Centre for Infection Research; Alemania
dc.description.fil
Fil: Schulze, Kai. Helmholtz Centre For Infection Research; Alemania
dc.description.fil
Fil: Cargnelutti, Diego Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
dc.description.fil
Fil: Scodeller, Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
dc.description.fil
Fil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research; Alemania
dc.journal.title
Pharmaceutics
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1999-4923/15/3/912
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/pharmaceutics15030912
Archivos asociados